NEXEL is excited to participate in the 48th Workshop of the Korean Society of Non-Clinical Study (KSNS), taking place at JEJU ICC!

 

Visit us at Booth #41 to explore the latest advancements in iPSC-based non-clinical testing and human-relevant research models.

 

As a leader in iPSC-derived technologies and next-generation NAMs (New Approach Methodologies), NEXEL is committed to transforming non-clinical research through innovation and collaboration.

 

At KSNS, we’ll be showcasing our comprehensive portfolio of:
• hiPSC-derived cell and organoid platforms
• Cardio-safety analysis services
• Customized CDMO solutions
— all designed to bridge the gap between non-clinical and clinical research.

 

If you’re attending the KSNS Workshop, we’d love to meet you!

 

Let’s discuss how NEXEL’s technologies can empower The Preeminent Clinical Studies from Distinguished Non-clinical Researches and accelerate your R&D goals.

 

≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡≡

 

In the midst of a global economic paradigm shift and the revolution of knowledge and light, our society has entered a new era of communication and innovation. Even under unprecedented circumstances, our unwavering passion for new drug development has led to The Preeminent Clinical Studies from Distinguished Non-clinical Researches (青出於藍 靑於藍).

 

We are pleased to invite you to the 48th Workshop of the Korean Society of Toxicology, a gathering to celebrate and share our collective progress.

 

This year’s workshop is designed to provide a comprehensive overview of the latest trends and practical strategies in drug development.

 

Session 1 will explore new directions in global and domestic R&D strategies for Alzheimer’s disease therapeutics, focusing on innovative biotech platforms.

 

Session 2 will discuss translational approaches from non-clinical to clinical research, featuring case studies in MASH treatments, OX40L/TNFa agonists, immunocytokines, and rare disease therapeutics.

 

Sessions 3 & 4 will cover AI-driven drug discovery, biomarker strategies from the clinical researcher’s perspective, and CAR-T/Bispecific Ab–TPD-based modalities, encompassing both conceptual and practical insights for next-generation drug development.

 

Session 5 will highlight Althera’s ALT-B4 and VUNO’s VX-149 (Unafra®) case studies, emphasizing the transition from biologics to NDA success strategies. The Young Scientist Award will recognize the passion and growth of emerging researchers, while the T2B Satellite Session will share outcomes and future directions of translational research connecting bench to bedside.

 

Following the Dinner Seminar, a dedicated Social Networking Session will provide an opportunity for participants to exchange ideas, recognize each other’s efforts, and strengthen collaboration beyond the boundaries of their busy schedules.

 

This workshop also marks the conclusion of the 17th term of our Clinical Committee — a meaningful moment to reflect on the past two years of progress and to prepare for a renewed start with our valued members and colleagues. We extend our sincere gratitude for your continued passion and support, and we look forward to an inspiring gathering in Jeju this year.